Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. Pharmacopeia Offers Help In Aftermath Of China's New Scandal, Cover-up Involving Deliberate Adulteration

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Repercussions following China's new contamination scandal involving the toxic chemical melamine are rippling across the Pacific, with potential importers in the U.S. alarmed over the effectiveness of China's food and drug safety system

You may also be interested in...



Cost Of China Healthcare Reforms Exceeds RMB 1 Trillion; Government Raises Reimbursement Ceilings

BEIJING - As leaders in China's central government gathered last week in Beijing to take part in the National People's Congress, they revealed that the price of ever-expanding healthcare reforms, ultimately aimed at providing universal coverage and commonly affordable medical care through measures including the national Essential Drug List, has already risen above RMB 1 trillion

Cost Of China Healthcare Reforms Exceeds RMB 1 Trillion; Government Raises Reimbursement Ceilings

BEIJING - As leaders in China's central government gathered last week in Beijing to take part in the National People's Congress, they revealed that the price of ever-expanding healthcare reforms, ultimately aimed at providing universal coverage and commonly affordable medical care through measures including the national Essential Drug List, has already risen above RMB 1 trillion

China Takes "Baby Steps" Toward More Open Supplement Regulation

China's health product regulators are taking "baby steps" toward more streamlined approval of supplements, but multi-ingredient products likely will face a series of hurdles before market, says Jeff Crowther, former executive director of the Natural Products Association's Beijing office

Latest News
UsernamePublicRestriction

Register

SC073071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel